The steroid internal use method for patients with IgA nephropathy

The steroid internal use method for patients with IgA nephropathy - The steroid internal use method for patients with IgA nephropathy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000032031

Enrollment

100

Registered

2018-04-01

Start date

2018-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IgA nephropathy

Interventions

Prednisolone 0.5mg/kg/every other day group Prednisolone 0.25mg/kg/everyday group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. The patients who proved IgA nephropathy by renal biopsy 2. Indication of steroid therapy

Exclusion criteria

Exclusion criteria: Patients desided by the doctor to be unsuitable to use the study other than above

Design outcomes

Primary

Measure	Time frame
In-urine proteine quantity, Urinary sediment finding, eGFR, IgA/C3 rate, Steroid side effect	—

Countries

Japan

Contacts

Public ContactHitoshi Suzuki

Juntendo University Department of Nephrology

shitoshi@juntendo.ac.jp03-5802-1065

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026